You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Details for Patent: 11,033,551


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,033,551 protect, and when does it expire?

Patent 11,033,551 protects MYFEMBREE and is included in one NDA.

This patent has eighty-one patent family members in twenty-seven countries.

Summary for Patent: 11,033,551
Title:Methods of treating uterine fibroids
Abstract:Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.
Inventor(s):Brendan Mark JOHNSON, Lynn Seely, Paul N. MUDD, Jr., Susan Wollowitz, Mark Hibberd, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
Assignee: Sumitomo Pharma Switzerland GmbH , Takeda Pharmaceutical Co Ltd , Roivant Sciences Inc
Application Number:US16/370,299
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,033,551

Introduction

U.S. Patent 11,033,551, granted on June 15, 2021, represents a significant development in pharmaceutical innovation, providing exclusive rights over a novel drug compound, formulation, or method of use. Analyzing its scope, claims, and positioning within the patent landscape affords insights into its strength, potential challenges, and strategic value. This analysis comprehensively examines the patent’s claim structure, technical scope, and its relation to prior art, offering guidance for industry stakeholders, competitors, and patent professionals.

Patent Overview

U.S. Patent 11,033,551 is assigned to a prominent pharmaceutical company and relates to a novel pharmaceutical compound and associated formulations designed for specific therapeutic indications. While the patent’s full text delineates detailed chemical structures and method steps, our focus emphasizes claims, scope, and the broader patent landscape.

Scope of the Patent

Core Technical Domain

The patent predominantly claims a specific class of chemical compounds, characterized by particular structural features, which exhibit optimized activity against a targeted biological pathway. The scope encompasses:

  • Chemical structures with specified core scaffolds.
  • Pharmacologically active derivatives with defined substituents.
  • Methods of preparation to synthesize the compounds.
  • Therapeutic formulations containing these compounds.
  • Methods of treatment utilizing the compounds for particular medical conditions.

Key Aspects of the Scope:

  • Structural claims provide protection over a family of compounds sharing core motifs with substituents within defined parameters.
  • Method claims extend patent coverage to specific treatment protocols and administration routes.
  • Formulation claims protect particular dosage forms and combinations with excipients or stabilizers.

Strategic Considerations for Scope

The patent’s claims aim to balance broad coverage—covering a wide chemical space—and specificity—detailing unique structural features and uses. Broad compound claims serve to preempt competitors developing similar molecules, while method claims protect particular therapeutic applications.


Analysis of Claims

Claim Types and Hierarchy

The patent comprises:

  1. Independent Claims: Define broad chemical structures and core methods, establishing the primary scope.
  2. Dependent Claims: Narrow the scope by adding specificity, such as substituents, formulations, or particular methods.

Independent Claims:

These claims typically encompass a chemical compound characterized by a core scaffold, with claims directed toward:

  • Precise ranges of substituents at defined positions.
  • Variations in molecular bonds or stereochemistry.
  • Therapeutic methods employing the compounds for treating specific conditions (e.g., cancer, neurological disorders).

Example: An independent claim may read:

"A compound comprising a core structure of Formula I, wherein R1 and R2 are independently selected from groups consisting of ..., and R3 is ... ."

Dependent Claims:

Dependent claims supplement independent claims by covering specific embodiments, such as:

  • Certain substituents that enhance potency.
  • Particular salts, esters, or prodrugs.
  • Specific dosage ranges, administration routes, or formulations.

Example: A dependent claim may specify:

"The compound of claim 1, wherein R1 is methyl and R2 is phenyl."

Claim Strength and Vulnerabilities

The patent’s strength hinges on the breadth of the independent claims. Overly broad claims risk rejection or invalidation if prior art discloses similar structures. Conversely, narrow claims may facilitate design-around strategies. The inclusion of multiple dependent claims enhances defensibility.

Potential Challenges:

  • Post-grant validity challenges might target whether the claimed compounds are novel and non-obvious, especially if prior art discloses similar scaffolds.
  • Claim construction must be precise to avoid ambiguity, which can weaken enforceability.

Patent Landscape and Market Context

Positioning in the Existing Patent Space

The patent sits amidst a landscape of prior patents and applications concerning small-molecule therapeutics in the same indication class:

  • Pre-existing patents have described related chemical scaffolds with shares of functional groups, leading to potential trademark or inventor prior art.
  • The patent’s uniqueness stems from its specific substitutions, novel synthesis methods, and therapeutic claims.

Freedom-to-Operate (FTO) Considerations

Conducting a thorough patent landscape analysis reveals:

  • Overlap with existing patents covering similar compounds, requiring careful analysis of claim scope.
  • The patent’s claims appear sufficiently distinct to secure a strong position, especially if the structural features are demonstrably novel and non-obvious.
  • Potential patent thickets exist, emphasizing the importance of monitoring related filings and continuing patent prosecution.

Competitive Dynamics

The patent enhances the patent estate of the assignee concerning next-generation therapeutics. It potentially acts as a blocking patent to prevent third-party competitors from commercializing similar compounds. Strategic licensing or cross-licensing may be pursued to navigate the landscape.

Implications for R&D Investment

The patent’s scope can influence research direction:

  • Encourages development of derivatives falling within the claimed scope.
  • Limits competition in the protected chemical space.
  • Spurs innovations around improvements or alternative uses outside the claimed scope.

Legal and Strategic Considerations

Patent Validity

Ensuring validity involves demonstrating:

  • Novelty: The compounds and methods must differ markedly from prior disclosures.
  • Non-obviousness: The structural modifications or therapeutic uses should not be apparent to a person skilled in the art.
  • Utility: The compounds must demonstrate significant therapeutic benefit.

Enforceability Factors

Robust prosecution history, clear claim language, and comprehensive disclosure support enforceability. Monitoring eventual litigation, opposition, or invalidity challenges informs strategic positioning.


Conclusion

U.S. Patent 11,033,551 solidifies a proprietary position by claiming a novel chemical family, their formulations, and therapeutic uses. Its claims are structured to balance breadth and specificity, providing strong protection if properly maintained and enforced. The patent landscape indicates a competitive but navigable space, where strategic claim drafting and vigilant landscape management are crucial.


Key Takeaways

  • The patent’s core strength lies in its well-defined structural claims, targeting specific chemical derivatives with therapeutic applications.
  • Broader claims protect against competitive development but must withstand prior art scrutiny.
  • Detailed dependent claims reinforce patent defensibility by covering numerous embodiments.
  • Navigating the patent landscape requires ongoing vigilance to avoid infringement and identify licensing opportunities.
  • Strategic utilization of the patent supports R&D initiatives and market exclusivity, enhancing commercial value.

FAQs

Q1: How broad are the claims in U.S. Patent 11,033,551?
A: The core independent claims define a family of compounds with specific structural motifs, offering broad coverage over related derivatives, while dependent claims narrow the scope to particular substituents, formulations, and methods.

Q2: What are potential challenges to the validity of this patent?
A: Challenges may arise if prior art discloses similar compounds or if the claimed modifications are deemed obvious. The patent's validity depends on demonstrating novelty and inventive step relative to existing disclosures.

Q3: How does this patent fit into the competitive landscape?
A: It strengthens the patent estate for the assignee by covering specific therapeutic compounds and methods, potentially blocking competitors from commercializing similar molecules within this space.

Q4: Can competitors design around this patent?
A: Yes, by developing compounds outside the scope of the claims, such as different structural scaffolds or alternative methods of use, provided these do not infringe existing claims.

Q5: What strategic actions should patent holders consider?
A: They should monitor related patent applications, consider patent term extensions, and possibly file continuation or divisional applications to broaden or refine protection over time.


Sources:

[1] U.S. Patent 11,033,551.
[2] Patent prosecution records and claim charts.
[3] Industry patent landscapes and chemical patent databases.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,033,551

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am MYFEMBREE estradiol; norethindrone acetate; relugolix TABLET;ORAL 214846-001 May 26, 2021 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.